Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mirgeal Gel is an oral dietary supplement formulated to relieve symptoms of gastroesophageal reflux disease (GERD) and non-erosive reflux disease (NERD), such as heartburn, chest pain, and acid regurgitation. Developed by PharmExtracta and distributed in Thailand by Great Eastern Drug, the product is a combination of sodium alginate, licorice root extract (*Glycyrrhiza glabra*), and a standardized bilberry extract (*Vaccinium myrtillus*, specifically Mirtoselect). The sodium alginate forms a physical gel barrier (raft) on top of the gastric contents to mechanically prevent acid reflux. The licorice extract provides anti-inflammatory and anti-ulcer properties, while the bilberry extract promotes cytoprotection and re-epithelialization of the gastric and esophageal mucosa. Mirgeal Gel is administered orally as a gel stick pack.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mirgeal Gel.